【 Lupus erythematosus is also known as the cancer that does not die » systemic lupus erythematosusIt is sometimes described as "the cancer that never dies"., because it is a long-term autoimmune disease. Its most noticeable symptom is the appearance of butterfly-like erythema on the cheeks. Although there is no best way to do so, the disease can be controlled through standardized science. Many patients are diagnosed and ask, "Why do I have lupus erythematosus?"Current studies have found that the onset of lupus erythematosus tends to run in families, which means that genetic factors may be related to its onset. Most of the patients are women between the ages of 15 and 40, and it is also known as "beauty disease". In addition, environmental factors such as sunlight, certain medications, and chemical agents can also contribute to the onset of lupus erythematosus.
Systemic lupus erythematosus is an autoimmune disease that causes long-term inflammation in the body and damage to multiple organs, but we don't know exactly what causes it. This disease can affect multiple organs and systems. At present, antimalarials, steroids, and immunosuppressive drugs are mainly used. While these traditional medications can reduce autoimmune reactions, they can cause a lot of *** and don't work well in some patients.
Numerous studies passedDiscovery of microbiota genome sequencingPatients with systemic lupus erythematosus have different levels of intestinal microbiota disorders, and there is evidence that translocations and immune imbalances caused by abnormal intestinal microbiota play an important role in the pathogenesis of SLE. Microbiota transplantation is an emerging intervention that has shown satisfactory results in several immuno-inflammatory-mediated diseases, including type I diabetes, ulcerative colitis, and melanoma patients who are resistant to PD-1 drugs**.
As a global leader in precision microbiota transplantation, Chengge Pharmaceutical Group was launched as early as 2021 together with the ** Disease Hospital of the Chinese Academy of Medical SciencesThe first multi-center clinical trial of microbiota transplantation** in active systemic lupus erythematosus in China, which will provide important evidence-based medical evidence for the application of microbiota transplantation technology in autoimmune diseasesThis clinical study provides important evidence-based medical evidence for the application of microbiota transplantation technology in autoimmune diseases.
In 2022, Zhao Ming, Lu Qianqian, and their team published the latest article in the Journal of Autoimmunity, in which the team conducted a single-arm clinical trial on the safety and efficacy of precision microbiota transplantation in patients with systemic lupus erythematosus. This is a 12-week, single-arm pilot clinical trial in which patients with active systemic lupus erythematosus are administered orally to live liquid enteric-coated capsules (All capsules are from Chengge Biotechnology***Conduct**.
Research Results:
A 12-week, single-arm clinical trial of 20 patients with systemic lupus erythematosus was included in the oral administration of encapsulated flora from a healthy donor while receiving routine**
FMT was well tolerated, with no serious adverse effects recorded except for transient gastrointestinal symptoms;
42.12% of patients metThe primary endpoint SLE response index 4, disease activity index, urine protein level and serum anti-dSDNA titer were significantly reduced
PMT significantly improves the patient's intestinal flora while upregulating the content of short-chain fatty acids.
【About the ** Disease Hospital of the Chinese Academy of Medical Sciences】
The Chinese Academy of Medical Sciences ** Disease Hospital The Chinese Academy of Medical Sciences ** Disease Research Institute (hereinafter referred to as the Institute) was founded in Beijing in 1954, the original name of the Institute of Venereal Diseases, set medical treatment, scientific research, prevention and control, education in one, is the first after the founding of the People's Republic of China to engage in the first disease, venereal disease, leprosy only national professional institutions, is now the Chinese Center for Disease Control and Prevention STD Control Center, leprosy control center, World Health Organization Sexually Transmitted Disease Prevention and Control Collaborating Center, Medical Fungal Preservation Sub-center of National Pathogenic Microbial Bacteria (Virus) Species Preservation Center, Key Discipline of the Ministry of Education, National Key Clinical Specialty, Doctoral and Master's Degree Conferring Point of Disease and Venereology of Peking Union Medical College, Postdoctoral Mobile Station;It has established the Key Laboratory of the Chinese Academy of Medical Sciences, the Key Laboratory of Jiangsu Province, the Provincial Clinical Medical Research Center, and the Provincial Biological Specimen Bank of Major Diseases. He edited and published the Chinese Journal of Venereology and the International Journal of Venereology (English edition). Won the national scientific and technological progress.
There are 7 national scientific and technological achievement awards such as the first and second prizes, and more than 90 ministerial and provincial awards. In 1964, the first director of the institute, Professor Hu Chuanhua, announced on behalf of the country that "the control and elimination of syphilis in China" was one of the important achievements of China's public health. At the end of the 20th century, leprosy was basically eradicated in China, and achievements that attracted worldwide attention were made.
In the past three years, it has ranked first in the science and technology value (STEM) of Chinese hospitals. He took the lead in the establishment of the "National ** STD Specialty Alliance" and built an Internet hospital with an average daily outpatient volume of more than 5,000 people. Entering the new era, in accordance with the requirements of building a core base of medical science and technology innovation system, the institute focuses on the development of first-class disease disciplines and the national tasks of venereal disease and leprosy prevention and control, benchmarks the world-class first-class disease disciplines, builds world-class comprehensive medical institutions with outstanding specialty characteristics, strengthens talent training, and continuously improves the level of medical services, scientific and technological innovation capabilities and international influence"Healthy China" has made new and greater contributions